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Abstract: Background: Bacterial persistence to antibiotics relates to the phenotypic ability to survive
lethal concentrations of otherwise bactericidal antibiotics. The quantitative nature of the time–kill
assay, which is the sector’s standard for the study of antibiotic bacterial persistence, is an invaluable
asset for global, unbiased, and cross-species analyses. Methods: We compiled the results of antibiotic
persistence from antibiotic-sensitive bacteria during planktonic growth. The data were extracted
from a sample of 187 publications over the last 50 years. The antibiotics used in this compilation
were also compared in terms of structural similarity to fluorescent molecules known to accumulate
in Escherichia coli. Results: We reviewed in detail data from 54 antibiotics and 36 bacterial species.
Persistence varies widely as a function of the type of antibiotic (membrane-active antibiotics admit
the fewest), the nature of the growth phase and medium (persistence is less common in exponential
phase and rich media), and the Gram staining of the target organism (persistence is more common
in Gram positives). Some antibiotics bear strong structural similarity to fluorophores known to be
taken up by E. coli, potentially allowing competitive assays. Some antibiotics also, paradoxically,
seem to allow more persisters at higher antibiotic concentrations. Conclusions: We consolidated
an actionable knowledge base to support a rational development of antipersister antimicrobials.
Persistence is seen as a step on the pathway to antimicrobial resistance, and we found no organisms
that failed to exhibit it. Novel antibiotics need to have antipersister activity. Discovery strategies
should include persister-specific approaches that could find antibiotics that preferably target the
membrane structure and permeability of slow-growing cells.
Keywords: bacteria; antibiotics; resistance; persisters; dormancy; time–kill; membrane transport;
membrane transporters; lipopeptides
1. Introduction
Hobby [1] and Bigger [2] in the 1940s noted the survival of small fractions of bacteria in axenic
planktonic cultures of both Staphylococcus and Streptococcus spp. after sustained exposure to normally
bactericidal concentrations of the recently deployed antibiotic penicillin. They were also able to show
that this effective ‘differentiation’ of the cultures into sensitive and resistant cells was purely phenotypic
in nature; reinoculation of the survivors showed that they were just as susceptible as they had been in
the initial cultures. Bigger [2] referred to this surviving fraction of cells as ‘persisters’. The concept of
persistence to antibiotics was further elaborated by Greenwood, who detected exponential growth
of E. coli and Proteus mirabilis post exposure to unrelated antibiotics [3] and inferred the involvement
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of membrane permeability by changing the osmolality of the media [4–6]. However, the subsequent
interest in such phenotypic tolerance to antibiotics by phenotypic variability was sporadic at best,
and was only rekindled many decades later (e.g., [7,8]). The renewed scrutiny has now crucially shown
that bacterial persistence to antibiotics can lead directly to antibiotic resistance [9–12]. This is of great
importance since bacterial persisters have been found to cause recalcitrant clinical infections [13–18].
Nonetheless, early work implicating membrane transport in bacterial persistence to antibiotics [19] has
not attracted the same level of attention.
Around the same time, a related finding of phenotypic bacterial differentiation in laboratory
cultures was that the killing of E. coli exposed to UV radiation “ . . . is an exponential function of the
dose. As observed by Witkin [20] a change in the slope of the curve appears for survivals less than
10−2, as if 1 per cent of the bacteria had higher resistance” [21]. Given that penicillin kills only growing
cells [22,23], an obvious inference was that the surviving fraction might have escaped death by entering
some kind of a dormant or non-growing state, something that is in fact the norm in natural microbial
communities [24–27].
The phenotypes reflecting persistence to antibiotics are another manifestation of the mosaic
composition of any given bacterial population, which allows some cells to survive changes in otherwise
cytotoxic environments [28]. This individual diversity manifests, for instance, as differences in cell size,
macromolecular content, and gene expression in otherwise genetically identical populations [8,29–33].
From an evolutionary point of view, such strategies of phenotypic differentiation may be seen as ‘bet
hedging’ [34,35]. Cells better suited to surviving transient exposure to high concentrations of antibiotics
are slow-growing cells, which are a minority when the environmental conditions are conducive to rapid
cell multiplication (e.g., exponential phase in batch cultures) [7,8,36]. When the surrounding milieu
has been exhausted of nutrients, cell growth stagnates, and the cell fraction that persists to antibiotics
is somewhat higher (e.g., in the stationary phase in batch cultures) [37–40]. Any microorganism will
find itself in cycles continuously oscillating between these two extremes of cell growth [41,42] and
henceforth surviving exposure to antibiotics (or any other toxins) with different degrees of success.
The mechanistic phenomena causing individual cells to be slow growers in an otherwise
fast-growing population would be expected to involve systems than lend themselves to stochastic
molecular cycles, and necessarily involve at least two partners that serve to ‘flip’ the cells between
such growing and non-growing states. A subset of such pairs is known as toxin-antitoxin pairs [43–48].
The first of those described was the protein kinase HipA, a type II toxin of E. coli that inhibits protein
translation when stochastically active [49,50]. However, the role of 10 type II toxin-antitoxin systems in
antibiotic persisters has been derogated to be the confounded effect of a widespread bacteriophage
contamination of lab strains of E. coli [51,52] or has had their function reannotated based on new
experimental evidence (e.g., pasT) [53]. The porin hokB can stochastically dimerize in Gram-negative
bacteria, which leads to ATP leakage and a metabolic slowdown that increases the tolerance to
antibiotics [54,55]. Indeed, lowered levels of ATP are known to prime cells to tolerate stress, such as
an exposure to high concentrations of antibiotics [56–58]. Another mechanism that fits the cyclic and
stochastic nature of phenotypic variability is the build-up and energy-consuming repurposing cycle of
protein aggregation through the growth cycle of E. coli. This has been shown to exhibit differential
kinetics among individual cells. The rates at which cells re-process these protein conglomerates are
related to the length of their lag phases and their capacity to survive antibiotics [59–65]. The growing
list of cellular systems with genes that express stochastically now includes enzymes of central carbon
metabolism, such as lactate dehydrogenase, and enzymes of the tricarboxylic acid cycle [66,67].
It is clear that the quantitative nature of the data on bacterial persistence to antibiotics should be
an asset to exploit. An extensive compilation of the data from the now ubiquitous biphasic killing
assay [68], for example, might bring a level of numerical consensus to a field prone to the inconsistencies
often observed in work in bacterial physiology and between results from different laboratories. The data
compiled here, from a large sample of the numerical information available in the literature, reflect
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that aim, and draw attention to quantifiable differences in decisive drivers of tolerance to antibiotics,
such as the growth phase, antibiotic class, bacterial species, and culture media.
Since these variables can each reflect the physiology of a microbial population, we connected
them with the available information on the involvement of membrane permeability in tolerance to
antibiotics. We then integrated this with evidence that argues for a causal effect of membrane transport
of xenobiotics (e.g., antibiotics), as much as natural nutrient substrates, in persistence to antibiotics.
This survey brings into context the fact that as in any other living cell, antibiotics must first interact
with and, in most cases, cross the cell membrane(s) in order to reach their target(s) [69–73].
2. Results
2.1. Data Summary and Praxis
The data extracted covered information for 36 bacterial species (Table 1) and 54 antibiotics (Table 2).
The following variables were tabulated together with the percentage (against the control at time
zero) of cells growing post-exposure to antibiotics: Species, growth phase, antibiotic, MIC (minimal
inhibitory concentration), antibiotic dosage, and time (hours) of exposure to the antibiotic (Table S1).
As expected, E. coli had the most numerous records from studies with 32 different antibiotics, followed
by S. aureus and Pseudomonas aeruginosa, with 18 and 16 antibiotics, respectively (Figure 1). The median
of the percentage of bacterial cells surviving exposure to nominally lethal concentrations of antibiotics
spanned five orders of magnitude from 7 × 10−4% in P. putida to 100% in E. faecium (Figure 2). If we
consider species with 20 or more data points in total, this range was narrower, with the lowest level of
persistence starting at 0.01% in A. baumannii. The multidrug-resistant S. aureus MRSA was represented
in the top 10 species with an incidence of 5% of cells persistent to antibiotics.
Table 1. Bacterial species. List of the 36 bacteria species that appeared in the publications included
in this survey. For Enterobacter aerogenes, the name was kept as reported in the original publications
although it is currently named Klebsiella aerogenes. S. enterica was serotype Typhimurium. The list
was separated according to the Gram-staining properties of these bacteria with 20 species listed as
Gram-negative and 16 as Gram-positive. (*) Bacillus spp. and Clostridium spp. are known to form
spores. The persistence to antibiotics data for these spore-forming bacteria originated from work
carried out in planktonic cultures where these bacteria were germinating.
Gram Staining
Negative Positive
Acinetobacter baumannii Bacillus subtillis (*)
Borrelia burgdorferi Bacillus thuringiensis (*)
Brucella abortus Clostridium difficile (*)
Brucella melitensis Enterococcus faecium
Burkholderia cenocepacia Lactobacillus lactis
Burkholderia multivorans Listeria monocytogenes
Burkholderia pseudomallei Mycobacterium bovis
Burkholderia thailandensis Mycobacterium smegmatis
Enterobacter aerogenes Mycobacterium tuberculosis
Escherichia coli Staphylococcus aureus
Klebsiella pneumoniae Staphylococcus aureus MRSA
Proteus mirabilis Staphylococcus epidermidis
Pseudomonas aeruginosa Staphylococcus saprophyticus
Pseudomonas putida Streptococcus mutants
Salmonella enterica Streptococcus pneumoniae
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Table 2. Antibiotic classes. The first column lists the primary mechanism of action or target. The class
groups some of the antibiotics based on their known chemical similarity. We do not include mixtures
containing, e.g., the penicillinase inhibitor clavulanic acid. The count of antibiotics reached 54, which
included one mixture of antifolates in trimethoprim-sulfamethoxazole (TSM). In some publications, this
mixture was denoted as Co-trimazol, which here was included in the TSM tally. (*) Antibiotics considered
bacteriostatic that were included here based on their reported bactericidal activity: chloramphenicol [74–76],
azithromycin [77–79], clathromycin [78,80–82], clindamycin, erythromycin [82–85], doxycycline [86,87],
and tetracycline [86,88]. The rest of the antibiotics are considered primarily bactericidal.
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Figure 1. Antibiotics and bacterial species included in this survey. A total of 54 different antibiotics 
that were listed are represented by color-coded points along the list of 36 bacterial species. The 
bacteria were ordered according to the number of different antibiotics used in each species (n 
antibiotics). Most antibiotics were highly represented in the top four species. TSM is the antifolate 
mixture of trimethoprim and sulphamethoxazole. 
Figure 1. ti i ti ct i l s i i l i t i s r . t t l of 54 different antibiotics
that were listed are present d by color-c ded points along the lis of 36 bacterial species. Th bacteria
were order d according to the umber of differ nt ant biotics used n each species (n antibiotics).
Most antibiotics were highly represented in the top four species. TSM is the antifolate mixture of
trimethoprim and sulphamethoxazole.
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Persister assays are carried out using antibiotics at concentrations above their inhibitory 
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concentration of antibiotics used against their MICs, as measured in nearly half of the publications: 
Antibiotics were used at a median value of 40 times their MICs. The range of persisters clustered by 
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63% and 71% for erythromycin and metronidazole, respectively (Figure 3). We note that the latter is 
represented by only two data points. 
Figure 2. Bacterial species. total of 36 bacterial species ere listed in the order of the edian value
as plotted as box plots of the percentage of cells surviving the exposure to antibiotics in co parison
to time zero in time–kill assays, or in co parison to the control ithout antibiotics in one-ti e-point
experiments. The abscissa represents the spread of the data as log10 values of the percentage of
persisters. The edian value for the percentage of surviving cells is listed in the edian column
followed the total number of ti e points collected for each species (n).
Persister as ays are carrie o t si ti i i ti s ove their inhibitory
concentrations (co o l re rt I , i i l i i it r tr ti ). We co pared the
concentration of antibiotics se i st t eir I s, s e s re i early half of the publications:
Antibiotics were used at a median value of 40 ti es their I s. he range of ersisters clustered by
antibiotic also spread across five orders of agnitude, starting ith colistin at 0.001 and reaching
63% and 71% for erythro ycin and etronidazole, respectively (Figure 3). e note that the latter is
represented by only two data points.
The frequencies of persisters are known to differ according to the antibiotic used. This plausibly
reflects the nature of any active and varied metabolism in these cells [89]. After arranging these
antibiotics by class (Figure 4) and by mechanism of action (Figure 5), it is noticeable that the lowest
numbers of persisters were observed for those molecules that target the cell membrane while the
opposite was the case for antimetabolites, such as antifolates, and for inhibitors of protein biosynthesis,
such as macrolides. The former membrane-targeting antibiotics are lipopeptides, such as colistin,
daptomycin, and polymyxin B (Table 2). It is noteworthy that the intervals of the data represented in
Figures 3–5 came from the values from different time points of the biphasic killing assays. This explains
in part the distance between the quartiles along the box plots, such as that observed for teicoplanin,
among other antibiotics (Figure 3). Nonetheless, using the median values as a measure of the central
tendency permits the comparisons drawn here.
Antibiotics 2020, 9, 508 7 of 36
Antibiotics 2020, 9, x FOR PEER REVIEW 7 of 37 
 
Figure 3. Antibiotics. A total of 54 antibiotics were listed in the order of the median value as plotted 
as box plots of the percentage of cells surviving the exposure to each of these antibiotics in comparison 
to time zero in time–kill assays, or in comparison to the control without antibiotics in one-time-point 
experiments. The abscissa represents the spread of the data as log10 values of the percentage of 
persisters. The median value for the percentage of surviving cells is listed in the median % column 
followed the total number of time points collected for each species (n). 
The frequencies of persisters are known to differ according to the antibiotic used. This plausibly 
reflects the nature of any active and varied metabolism in these cells [89]. After arranging these 
antibiotics by class (Figure 4) and by mechanism of action (Figure 5), it is noticeable that the lowest 
numbers of persisters were observed for those molecules that target the cell membrane while the 
opposite was the case for antimetabolites, such as antifolates, and for inhibitors of protein 
biosynthesis, such as macrolides. The former membrane-targeting antibiotics are lipopeptides, such 
as colistin, daptomycin, and polymyxin B (Table 2). It is noteworthy that the intervals of the data 
represented in Figures 3–5 came from the values from different time points of the biphasic killing 
assays. This explains in part the distance between the quartiles along the box plots, such as that 
Figure 3. Antibiotics. A total of 54 antibiotics were listed in the order of the median value as plotted as
box plots of the percentage of cells surviving the exposure to each of these antibiotics in comparison
to time zero in time–kill assays, or in comparison to the control without antibiotics in one-time-point
experiments. The abscissa represents the spread of the data as log10 values of the percentage of
persisters. The median value for the percentage of surviving cells is listed in the median % column
followed the total number of time points collected for each species (n).
2.2. Bactericidal vs. Bacteriostatic Antibiotics
It is usual to contrast bacteriostatic antibiotics from those that are bactericidal [90], where we
use the operational ability of the target microbes to replicate at any time in the future as a criterion
of whether bacteria are or were ‘alive’ or not [91–93]. Specifically, as judged by colony formation,
bacteriostatic agents are considered merely to cause growth to cease, while bactericidal antibiotics
actually decrease the number of organisms whether they are growing or not. The distinction is mainly
based on in vitro measurements, and is much less clear cut in clinical situations [90,94,95]. Indeed,
there is evidence that bacteriostatic inhibitors may antagonize the activity of bactericidal molecules
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both in vivo and in vitro [96,97]. This important effect follows straightforwardly from the fact that
antibiotics are normally most potent against growing cells (e.g., [22,98–100]).
Clearly, in vitro studies are far easier to perform than are those in vivo, and we recognize that the
question of persistence is not easy to disentangle from simple bacteriostasis in vitro; organisms that
are exposed to a concentration of antibiotic that causes them to cease growth but not to die can by
definition regrow as soon as the bacteriostatic antibiotic is removed, and this is (or can be) a purely
phenotypic phenomenon. This is why we usually consider persistence in the context solely of normally
bactericidal antibiotics. Table 2 and the references therein set out those considered to fall into the two
classes. Macrolides, chloramphenicol, and tetracyclines primarily considered bacteriostatic, had levels
of persisters equivalent to 11.9%, 8%, and 1.26%, respectively (Figure 4).
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Figure 4. Persisters as compared by antibiotic classes. Antibiotics were g ouped into 19 different classes
ac ording to their known chemical similarity (Table 2). These antibiotic classes were listed in th order
of the median value as plotted box plots of the percentage of cells surviving the exposure to each of
these antibiotics in comparison to time zero in time–kill assays, or in comparison to the control wit out
antibiotics in one-time-point experi ents. Bacteriostatic antibiotics are underlined. The abscissa
represents the spread of the data as log10 values of the percentage of persisters. The median value for
the percentage of surviving cells is listed in the median % column followed by the total number of time
points collected for each species (n).
Given that bacteriostatic inhibitors do not in fact kill bacteria in vitro, it is of obvious interest to
wonder what is different about those that do. To this end, Collins and co-workers (e.g., [101–107])
showed that the main distinguishing feature was not in fact their targets (e.g., protein synthesis or
the cell wall or DNA topoisomerases) but, in significant measure, the extent to which they could
cause the cells to produce damaging free radicals [108–110]. Such bactericidal activities could kill
cells by inducing a state manifesting features equivalent to those accompanying apoptosis in higher
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organisms [111,112]. Clearly, any analysis of phenotypic persistence needs to recognize that there
are many gene products that might be more or less protective against oxidative stress at a single cell
level, and so consequently it is not necessarily surprising, as we show here, that its extent may vary
quite dramatically.
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Figure 5. Bacterial persisters compared by anti i i echanism of action. Antibiotics were separated
in 7 groups according to their main mechanism of action or target (Table 2). These groups were listed in
the order of the median value as plotted as box plots of the percentage of cells surviving the exposure
to each of these antibiotics in comparison to time zero in time–kill assays, or in comparison to the
control without antibiotics in one-time-point experiments. The abscissa represents the spread of the
data as log10 values of the percentage of persisters. The median value for the percentage of surviving
cells is listed in the median % column followed by the total number of time points collected for each
species (n).
2.3. Growth Phase and Gram Staining Were Related to Significantly Different Levels of Bacterial Persisters
to Antibiotic
As anticipated, bacteria in an ostensible stationary phase had a median value for persisters
that was circa 30 times higher than the median for persisters found in samples from exponential
cultures (Figure 6a, Table 3). This difference is a known trend (e.g., [38,61,113–119]), but here we are
able to state this quantitatively, together with its statistical significance (p < 1.1 × 10−10) (Figure 7a).
The data collated h re for bacteria in the exponential phase also included dat from cultures denoted
in some publications as “mid-exponential” and “late-exponential”. The distributions of t e data
from the publications using those terms were not different from the distribution of data from just
“exponential” cultures.
The type of culture media in which bacteria are growing was expected to be a modifier of the
outcome of antibiotic challenge in persister assays. These media were either complex and nutrient
rich, or defined with a more limited nutrient composition. Previous studies have shown that E. coli
growing in M9 minimal media, for instance, have fewer cells surviving a subsequent challenge with
4-quinolones (i.e., ofloxacin and ciprofloxacin) than when growing in complex media [52,120]. However,
the far more extensive data collected here showed no differences between complex and defined media,
with median values of 0.2% of persister cells in complex med a and 0.16% of pers s s cells in
defined media (Figures 6b and 7b). On e other hand, the median value of per isters was nine-fold
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higher in Gram-positive bacteria than in Gram-negative species (Figures 6c and 7c). With data from
20 Gram-negative and 16 Gram-positive bacterial species (Table 1) from this sample of publications,
this was possibly an unexpected observation and new to this field. Some of the Gram-positive species
of bacteria listed are known to be able to sporulate (Table 1), i.e., Bacillus and Clostridium. However,
the data included here for those bacteria originated from time–kill assays that used samples from
planktonic cultures in activate growth, implying germinated populations.
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the data were clustered according to the growth phase of the cultures used for the persister assays.
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Table 3. Descriptive statistics for three of the variables measured for the incident of persisters in
bacteria: The median, mean, and confidence interval 95% (CI95) were listed for the data grouped by
growth phase, Gram staining, and growth media. The total number of data points collected from source
are denoted as n.
Growth Phase Growth Media Type Gram Staining
Exponential Stationary Complex Defined Negative Positive
Median (%) 0.07 2.00 0.20 0.16 0.11 1.00
Mean (%) 12.6 26.8 17.2 19.9 12.7 27.1
CI95 (%) 10.0–15.1 23.3–30.3 15.1–19.4 12.8–27.0 10.9–14.5 22.2–32.0
n 1675 908 2248 335 1707 876
2.4. Trends of Time–Kill in Relation to Growth Phase, Media Type, and Gram Staining
The data from time–kill assays in antibiotic persistence have usually fitted (or been fitted to) a
biphasic curve. As originally modelled for E. coli challenged with quinolones, an initial exponentially
descending line observed within the first hour of exposure to antibiotics is followed by an asymptotic
decline in surviving bacteria that tends to zero [68]. In the data collated here, the first phase of the time
of killing was recorded from 10 min, with an exponential killing that continued for up to 10 h. The rest
of the recorded data extended up to hundreds of hours. The longest recorded time–kill point was 504 h
for M. tuberculosis challenged with ethambutol (Table S1) [121,122]. The differences in the fitted curves
of exponential versus stationary persisters were striking (Figure 8a). The persister minimum (time at
which the fewest number of persisters was recorded) for stationary cells was 4 h while it took 10 h
to reach that point in cells from exponential cultures. At this point (i.e., 10 h), the difference in the
number of persisters was two orders of magnitude, 1% versus 0.01% for stationary and exponential
cells, respectively.Antibiotics 2020, 9, x FOR PEER REVIEW 12 of 37 
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growth-dependent data showed triphasic phases for persisters from both exponential and stationary
cell cultures as desc ibed in the main text. Media type: The data grouped by media type showed no
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The fitted line of the time–kill assays as compiled here for all 36 bacterial species and 54 antibiotics
showed that cells growing in the exponential phase, on average, did not seem to converge into the
expected asymptotic line of the second phase of a biphasic killing assay (Figure 8a). On the contrary,
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an opposite trend was observed where the percentage of persister cells increased above the minimum
0.01% after 10 h of exposure for the majority of species (24 of the 36 bacterial species) represented
in this survey. This incremental trend of persisters was followed by the initiation of a plateau from
approximately 80 h of exposure to antibiotics (Figure 8a).
Cells originated from stationary cultures also had a trimodal time–kill curve (but one different from
the exponential growing data), whereby beyond the initial 3 h of exponential decline, the proportion
of persister cells stabilized at 1% for up to 10 h. Thereafter, the third phase saw the percentage of
persisters decline even further from 1% to approximately 0.01% (Figure 8a). Trimodal growth inhibition
curves have been observed in the early work on penicillin in S. faecalis and on 4-quinolones in E. coli,
with the antibiotic concentration as the independent variable [123,124]. It has also been observed in
time–kill assays with β-lactams in E. coli [5], and in other similar assays where bacterial growth was
re-initiated after deactivating the antibiotic using penicillinase [3]. Although these early findings do
not seem to be acknowledged in the modern literature, they were recapitulated in the data collected
here, which derived from work published since 2003. They plausibly reflect cells periodically emerging
from non-growing states to assess conditions, and then being killed off if unfavorable.
If the data are clustered by media type, the comparable levels of persisters between defined and
complex media diverged from each other beyond 100 h. Cells originated from cultures in defined
media had, at the longest times recorded, a percentage of persisters approximately 20 times higher
than those cells that originated from cultures in complex media: 2% and 0.1%, respectively (Figure 8b).
When the data were grouped by Gram-staining properties, Gram-positive bacteria had a monotonic
trend in the time–kill assay while a triphasic curve was seen again, this time for the fitted data, for the
Gram-negative bacteria (Figure 8c). In Gram-negative bacteria, the initial exponential kill phase
was followed by an incremental number of cells surviving after 10 h of exposure to antibiotics from
approximately 0.01% to 0.9% of persister cells. After 100 h, a further exponential decline reduced the
surviving cells to fractional percentages (10−4) (Figure 8c).
2.5. The Paradoxical Effect of Concentration on Bacterial Killing by Some Antibiotics
The most commonly used antibiotics were ciprofloxacin, ampicillin, ofloxacin, gentamicin,
vancomycin, and tobramycin, selected as antibiotics with 100 or more data points of the full data set
(Figure 3). These six antibiotics were used for the time–kill assays for 28 different bacterial species.
We then wished to explore the effect of incremental concentrations of antibiotics on the number of
surviving cells, with particular attention to the paradoxical trend of higher levels of persisters as
the concentration of antibiotics increases [125]. Four antibiotics had a sufficient amount of data for
the polynomial regression fitting (materials and methods): ampicillin, ciprofloxacin, gentamicin,
and ofloxacin.
The challenge of ampicillin showed a decline in persister levels proportional to the concentration
of antibiotic from 100 µg/mL and higher (Figure 9a). However, the fluoroquinolones ciprofloxacin
(Figure 9b) and ofloxacin (Figure 9d) induced an increase in the number of persister bacteria when used
at more than 0.15 and 0.5 µg/mL, respectively. This is of practical importance since the concentrations at
which these two antibiotics are frequently used in time–kill assays are higher: 1 µg/mL for ciprofloxacin
and 5 µg/mL for ofloxacin (Table S1 and pointed up by the vertical arrows in Figure 9). When used at
these high concentrations, ciprofloxacin killed 10-fold fewer bacteria than at the lower concentration of
0.15 µg/mL. In the case of ofloxacin, three-fold fewer bacteria were killed when used at 5 µg/mL than
when used at the lower concentration of 0.5 µg/mL. From this group of antibiotics frequently used in
time–kill assays, gentamicin appeared to be the only antibiotic to have been frequently used at the
concentration that killed the most bacteria and whereby the lowest number of persisters are observed
(Figure 9c).
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Figure 9. Effect of antibiotic concentrations on the levels of bacteria persistent to antibiotics:
The concentration of antibiotic is represented as the log10 of µg/mL along the abscissa of each
plot. The incidence of persister cells is represented also as the log10 of the percentage of cells growing in
solid media after exposure to antibiotics in comparison to the number of cells at time zero. The number
of persisters against time were fitted by local polynomial regression fitting by weighted least squares as
detailed in the materials and methods. The incubation times for any given concentrations of antibiotic
were also plotted with a color spectrum of blue to red for up to 100 h. The arrows point at the most
frequently used concentration for each antibiotic (mode of antibiotic usage in Table S1).
2.6. Top Six Bacteria
The top six bacteria ranked by the number of different antibiotics tested for persistence were
E. coli, S. aureus, P. aeruginosa, M. tuberculosis, A. baumannii, and S. aureus MRSA (Figures 9 and 10).
Importantly, this list includes three of the six species prone to developing rapid antibiotic resistant
(ESKAPE) [12,126]: S. aureus, A. baumannii, and P. aeruginosa. The other three ESKAPE species were also
represented in this survey although with fewer antibiotics: E. faecium, K. pneumoniae, and Enterobacter
spp. (E. aerogenes) (Table S1). The emphasis on these bacteria has been noted and reviewed for E. coli,
S. aureus, P. aeruginosa, and M. tuberculosis [127]. The data segregated by growth phase mirror the
general trend of cells from stationary cultures surviving the challenge to antibiotics better than those
that originated from exponentially growing cultures (Figure 9). By visualizing the data from these
individual species, it was obvious that studies seemed to concentrate on one or the other growth phase.
Thus, for instance, the results for some species, such as P. aeruginosa, were primarily from stationary
growing cultures while the rest of this group of bacteria had been tested mainly in exponential growth.
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Figure 10. Distribution of the dat f st studied bacteria species as grouped by growth
phase. The percenta ( l 10) of per isters to antibiotics as listed for each species wer ordered
by their median values. The growth phase of the cultures that underwent persistence tests were
differentially plotted, green for sa ples fro exponential cultures and orange for stationary cultures.
The red dotted lines represent the position at which levels of persister cells of 1% are in each box plot.
With the exception of the data for colistin in A. baumannii, the higher number of persisters found in
cells from stationary cultures exemplified here in the six most commonly studied bacteria species.
A similar and more pronounced bias was found for the influence of the type of culture media
on the outcome of antibiotic challenge (Figure 11). The majority of research for these six species of
bacteria was carried out with cells growing in complex media. The data from some antibiotics that
were studied with both defined as well as complex media showed E. coli cells growing in defined media
tolerated kanamycin better than cells growing in complex media, with the opposite trend observed for
ciprofloxacin (Figure 11). Similar scenarios were shown for rifampicin and isoniazid in M. tuberculosis,
although the differences in the median values were not significant in either E. coli or M. tuberculosis
(Figure 11). Outside these cases, the data from these species substantiated the general trend, with no
difference in the incidence of cells persistent to antibiotics between cells that originated from complex
media versus defined media.
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2.7. Cheminformatics of Antibiotics Represented in This Survey and Fluorophores Transported by E. coli
The data analyzed here provided the opportunity to compare the chemical space of those
54 antibiotics used on bacterial persistence studies with molecules known to be transported by bacteria.
Specifically, fluorescent molecules that are found to accumulate in E. coli [128] have great potential to
study membrane transport, a process of paramount relevance in the study of antimicrobials. We recently
reported 47 fluorophores as being able to enter E. coli with fluorescent signals two-fold or higher than
the background controls [128]. At first glance, important benchmarks provided confidence in the
cluster analysis. Antibiotics, such as penicillin and cephalosporins, clustered together as well as did
aminoglycosides. Also grouped together were related fluorophores, such as fluorescein derivatives
(i.e., 5′-carboxyfluorescein, 2′,5′-dicarboxyfluorescein, fluorescein) as well as the thiazoles neutral red,
acridine orange, pyronin Y, methylene blue, and oxazine 1.
The relevance of this structure similarity analysis became apparent with the antibiotic-fluorophore
groups observed in Figure 12. Three clusters were found with a Tanimoto similarity [129–131] of 0.77
or higher. The sulphonated fluorophores amaranth, sulphorhodamine B, and pyranine clustered with
the aminoglycosides streptomycin and amikacin. Another group contained the xanthene dyes eosin Y,
calcein, rhodamine 700, and rhodamine 800 included also tetracycline and doxycycline. A third cluster
contained trypan blue with rifampicin and daptomycin (Figure 11). Thus, three different classes of
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antibiotics found a structural cognate in the form of fluorescent molecules known to be transported
across the cell membranes of E. coli [128].
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3. Discussion
Bigger and contemporaries [1,2,88] had the exceptional insight of using an ordinary term that
embodies with great depth the scientific phenomena that they observed for the first time. A fractional
number of bacteria that survive lethal concentrations of antibiotics were named persisters [132].
To persist, these cells would be presumed to have distinctive traits pre-exposure and would emerge as
sole colonizers in the next round of growth when the antibiotic dissipates [3]. Those cells, however,
retain genotypic sensitivity to the given antibiotic and most of their progeny will be killed if exposure
to the antibiotic reoccurs. Nonetheless, and again a connotation given by the term, under iterative
exposure, persisters become gradually more tolerant to the stressor, and eventually resistant to
it [9–12,133,134].
The anticipated distinctive traits that allow bacteria to endure the lethality of high concentrations
of antibiotics are derived from the variability of cell growth, whereby slow-growing [32,135]—possibly
non-dividing [136]—cells of a population arise by the stochastic nature of molecular switches of cell
metabolism in bacterial populations in rapid growth (type II persisters) [8,137,138]. A different source
of cells that survive the presence of high concentrations of antibiotics are bacteria that find themselves
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under the eventual shortage of nutrients or have various other sources of stress, also denoted as type
I persisters [137,138]. While type II persisters can be regarded as deploying bet-hedging strategies,
type I persisters are cells that deploy strongly evolutionarily selected responses against expected stress
pressures [32,108,139–142]. A well-known case among the latter is nutrient scarcity and the associated
responses [40,58,139,143], such as what occurs in the case of the stationary growth phase of a bacterial
batch culture, which we showed here generates approximately 30-fold more persisters than do the
exponentially growing populations. With up to a third of cells in stationary cultures surviving lethal
concentrations of antibiotics (Table 3), a significant proportion of cells in wild populations—where
limited sources are the norm—are expected to be able to mirror this high level of tolerance to stress.
There is in effect an epigenetic memory of individuality in growing cells [59,62].
As a novel observation, Gram-positive bacterial persistence to antibiotics surpassed that of
Gram-negative bacteria by an order of magnitude. Since the survival in the face of lethal concentrations
of antibiotics is compiled here for different antibiotics and different bacterial species, an intrinsic
mechanism, such as the distinctive cell wall of the Gram-positive bacteria [144,145], seems to be at play
to enable a more effective protection than in their Gram-negative counterparts. The peptidoglycan
wall of Gram-positive bacteria (which may be ~13 times thicker than in Gram-negative bacteria [146])
is functionalized with lipidic complexes of teichoic acid regularly attached to N-acetylmuramic acid
residues, which makes the total mass of teichoic acid derivatives approximately 60% of the cell wall
mass in B. subtilis and S. aureus [147]. Accordingly, impaired biosynthesis of teichoic acids—which
have a negatively charged backbone—renders S. aureus MRSA sensitive to β-lactam antibiotics [148].
In this regard, new antibiotics, such as teixobactin, which impair the assembly of the Gram-positive
cell wall by binding lipid substrates, have led to great expectations [146] that seem to be well grounded
based on the findings of this survey.
We attribute the increased number of persisters observed at time points beyond 80 h in time–kill
assays to the reduced stability of antibiotics at 37◦C for those lengths of time [149]. This is particularly
noticeable when the concentrations of antibiotics used are near the MIC for a given bacterial species
and antibiotic pair [122,150–153]. Levofloxacin had to be present at 4-fold its MIC for V. vulnificus to
avoid re-growth throughout the time–kill assay [150], ceftibuten had to be at 100-fold the MIC for the
same reason in Enterobacteriaceae [151], and similarly, for gentamicin and penicillin in S. faecalis and
S. aureus, respectively, with re-growth at 13 h when antibiotics were at their MICs [122,153]. In an
in vitro pharmacokinetic model with E. coli at 1 h of antibiotic elimination time, growth was observed
at the MIC, with a bactericidal effect only when the antibiotic was at 10-fold its MIC [152].
Unexpected growth can also be observed at antibiotic concentrations above their inhibitory
concentrations—MIC—in what has been known as paradoxical growth or the Eagle effect [125,154] and
seen here in three of the four antibiotics most used in time–kill experiments (Figure 9). The exposure to
the two fluoroquinolones ciprofloxacin and ofloxacin, and the aminoglycoside gentamicin produce an
increasing number of persisters above 0.15, 0.5, and 0.75 µg/mL, respectively. Examples of an in vitro
more-drug-kills-fewer Eagle effect include vancomycin against C. difficile [155] and fluoroquinolones
against M. smegmatis [156]. An in vivo model illustrated this effect in C. diphtheriae treated with
amoxicillin [157]. Not every bacteria/antibiotic pair assessed has shown this trend and the reports vary,
for instance, for β-lactams [158]. In the light of these findings, it is logical to include as a prerequisite
the optimal concentration of antibiotic for a persister assay so the survivors are not an overestimation
and ultimately not an unprincipled reflection of persistence. This is particularly so since the relation
between persistence to antibiotics and the Eagle effect is unknown, although there have been attempts
to draw similarities [154].
Antibiotic persistence is a prominent example of the interdependence of deterministic and
stochastic mechanisms in the bacterial life cycle [159]. A case in point with accumulating evidence is
the aggregation of endogenous proteins and its proportionality to the rate of cell growth (i.e., individual
bacteria epigenetic memory [63]) throughout a period of rapid proliferation [160]. Necessary but much
less predictable is the asymmetric segregation among the daughter cells of these protein aggregates [62]
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(which are essentially damaged components). A second layer of stochasticity is introduced by the
variability of individual cells in repairing and recycling these aggregates. Bacteria slow at recycling
protein aggregates in the lag phase tend to have higher proportions of cells persistent to antibiotics than
their more competent siblings [60,61,63]. A similar scenario is the accumulation of glycogen in bacteria
during rapid growth, which then fuels cell growth in lag phases with significant interindividual
variability [161,162]. However, a potential link of the latter with bacterial persistence to antibiotics has
not been explored. The cell-to-cell variability in the cyclic aggregation and reuse of macromolecular
cell components along the bacterial life cycle is of particular relevance in the study of persisters.
For instance, the recycling of endogenous protein aggregates and the number of persisters throughout
the lag phase follow the same long tail exponential decay kinetics [64,163].
The data compiled here indicate that bacteria have fewer persisters to antibiotics that directly
interact with and target the cell membrane (i.e., lipopeptides and mitomycins). This is consistent
with the body of evidence that cell membranes are a battleground for the asymmetrical partitioning
of cytoplasmic contents in cell division, a prevailing source of fluctuation in the bacterial cellular
make-up. Diaminopimelic acid is an intermediary of amino acid and peptidoglycan metabolism, which
accumulates into the old poles of E. coli, as part of the model of asymmetric elongation and division
of the cell wall [164]. The proteinaceous content is heterogenous along the periplasmic space of the
long axis and poles of E. coli [165]. As the medium acidifies during rapid proliferation, rod-shaped
bacteria inheriting the older pole divide more slowly than do the cells inheriting the newer pole [166].
An example of specific membrane transporters differentially captured in this old and new pole lineage
diversification is the Ser chemoreceptor prompt [162,166–169]. The segregation of damaged cargo
can also be drastically addressed by bacteria producing small spherical non-proliferating (lack of
chromosomal DNA) minicells. Bacterial strains vary in their capacity to generate minicells and those
that do tend to be more tolerant to antibiotic-induced stress [170].
Membrane transport has been an underlying aspect of bacterial survival to lethal concentrations of
antibiotics since the initial reports of this phenomenon [6]. This was complemented by the finding that
Enterobacter survival to ceftriaxone [171] and P. aeruginosa to beta-lactams [172] is mediated by decreased
expression of outer membrane proteins (OMPs). Further examples of enhancement of persisters are
bacteria with increased activity of effluxer systems, such as TolC [173] and E. coli with an impaired
BtsSR/YpdaB pyruvate sensing system [174]. Crucially, there is also precedent of modifications in
membrane transport systems that sensitize bacteria to the bactericidal effects of antibiotics. Inactivation
of phoU (Pho transporter) induces a metabolic hyperactivity that renders E. coli and M. tuberculosis more
sensitive to antibiotics and other stressors [175,176]. Similarly, the induction of transport of exogenous
L-tryptophan makes E. coli less tolerant to aminoglycosides [177]. Inactivation of ATP-dependent
high-affinity potassium (K(+)) transporter in M. tuberculosis causes membrane hyperpolarization,
increased intracellular ATP, and reduced persisters to rifampicin [178]. The strongest case might
be presented by the anthelmintic bithionol, which has been brought forward as a candidate for
repurposing as clinically bactericidal, with selective activity against S. aureus MRSA [179]. Bithionol is
stated to embed selectively into bacterial (and not mammalian) lipid bilayers [179], increasing
membrane permeabilization and membrane fluidity. Together with the data from the effects of other
membrane-active antimicrobial agents, such as nTZDpa [180], the work collated here presents a strong
case for membrane-active compounds to carry the highest antipersister potency.
The development of platforms for antipersister antimicrobials discovery is a vital necessity.
This involves searching for compounds that interact and successfully target or cross the membrane(s)
of slow-growing or non-dividing bacteria [181]. Clustering the set of fluorophores accumulated by
E. coli [128] and the antibiotics listed in this report (Figure 12) by chemical structure similarity points at
a strategy to explore a potential antipersister pharmacopeia. The structural similarity of daptomycin to
trypan blue, for instance, could enable the search for membrane-targeting antibiotics. Daptomycin is a
cyclic lipopeptide and membrane-active antibacterial from Streptomyces roseosporus. However, due to
the intrinsic tendency of membrane-active compounds to have cross toxicity with mammalian cells,
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the capacity to explore a wide chemical space by high-throughput chemical synthesis and screening is
necessary to increase the odds of identifying compounds with the desirable specificity.
4. Materials and Methods
The scientific literature database PubMed (https://pubmed.ncbi.nlm.nih.gov/) was searched with
the following query: antibiotic AND persister AND bacteria AND English[lang] NOT review[ptyp].
The abstracts or titles (if no abstract was available) of a total of 9047 results up to 30 April 2020 were
screened for the keywords (in any order): in vitro, persister, bacteria and (proportion or incidence or
measure). This was carried out with a grep bash routine in Linux and iterative manual screening of
selected papers. At this point, it became apparent that the great majority (over 90%) of publications
(dating back to 1946 in PubMed) from the initial search were not relevant to this data compilation.
They had vaguely used the terms ‘persistence’ or ‘persister’ for chronic infections and/or to denote certain
pharmacokinetic properties of antibiotics and other medications under investigation. Publications on
eukaryotic microorganisms (yeasts) (e.g., [182]) and Archaea (e.g., [183]) were also excluded.
A selection of 847 primary publications deemed relevant to the theme of antibiotic bacterial
persisters were manually surveyed for quantitative data from work carried out in planktonic cultures.
Numerical data were finally extracted from 187 articles [3,4,7,8,11,12,36,39,40,49,51,52,55–58,61,66–68,
89,115–117,119,121,122,126,133,141–143,150,163,173,177,184–334] (Table S1) published between 1970
and 2020 and reporting persister assays for antibiotic-sensitive bacteria strains. The data represented
levels of persisters as percentages of cells growing as colony-forming units—cfu—on solid media
after exposure to antibiotics for one or more time points in comparison with the sample at time zero.
When the cfu post-antibiotic were not explicitly stated, numerical data were estimated by visual
inspection of the relevant plots. The growth phase of the batch cultures from which the bacteria tested
for persistence to antibiotics originated (i.e., exponential phase or stationary phase) was recorded as
stated in each study. Numerical data were represented with three significant figures, with the exception
of the very small quantities of the data for the lowest levels of persister.
Plotting and statistical analyses were carried out using R (https://www.r-project.org/).
The hierarchical dendrogram and heatmap of the palette of 47 fluorophores were scripted with
R’s dendextend and ggplot’s heatmap.2 packages. The hclust function of dendextend produced hierarchical
clusters from a Tanimoto similarity matrix derived as follows: cheminformatic (structural) fingerprints
of 47 fluorophores were derived from their InChl notation using the Patterned algorithm within the
RDkit (www.rdkit.org/) nodes in KNIME (http://knime.org/) [129,335]; a Tanimoto distance (TD) matrix
was generated from these fingerprints (KNIME’s Distance Matrix Calculate); and the scores of this
matrix were converted to Tanimoto similarity indices (1-TD) using KNIME’s Similarity Search.
The fitting of the time–kill data was carried out as implemented in R’s ggplot loess (local
polynomial regression fitting) method. Local fitting uses the distance of data in the neighborhood of
each dependent variable (time) to weight the least squares of the independent variable (count of cells
of persisters after each time point of incubation). The size of the neighborhood is controlled by the
ggplot’s span parameter in geom_smooth or stat_smooth. The default span applied here uses tricubic
weighting (proportional to (1 − (distance/max distance)ˆ3)ˆ3) [336].
5. Conclusions
Bacteria can tolerate lethal concentrations of antibiotics with cells that are slow growers in an
otherwise rapidly proliferating population. Deploying different mechanisms, bacteria undergoing
growth-limiting conditions can also survive—in higher proportions (30-fold difference)—the presence
of antibiotics. Species represented here are those clinically considered of high priority, usually those
with a high incidence of antibiotic resistance (e.g., ESKAPE species), with E. faecium leading the table
of antibiotic persisters. The most tested antibiotics (fluoroquinolones, penicillins, aminoglycosides,
and cephalosporins) had similar persister levels of 0.12–0.16%. Lipopeptides (membrane-active
compounds) were similarly represented but with half the levels of persisters, 0.05%. Two of the
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fluoroquinolones (ciprofloxacin and ofloxacin) and gentamicin exemplified here the Eagle effect, where
higher concentrations of antibiotic can be less cytotoxic. This serves as a reminder of the need for
optimization of bacteria–antibiotic concentration combinations before the surviving cells from time–kill
assays can be interpreted as persisters. The cell wall of Gram-positive bacteria seems to give them
an advantage point to tolerate bactericidal concentrations of antibiotics. Since most antibiotics are
bactericidal against rapidly growing bacteria, not against slow-growing organisms, the activity seen
by lipopeptides producing low levels of persister cells is encouraging. To this extent, we point at the
strategy offered by fluorescence-based screening with a validated palette of fluorophores known to be
accumulated in E. coli. The need for discovery platforms for antipersister antimicrobials cannot be
overstated [22,23,337]. The road map from this sample of 50 years of quantitative bacterial persister
data, rather clearly, is guiding us to strive for finding bactericidal compounds that can traverse or are
active against bacteria-specific cell membranes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/8/508/s1,
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